Novo Nordisk

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsve¦rd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries.

History

The company was founded in 1923 and is one of the world's leading providers of diabetes care products, including insulin and other diabetes-related drugs. Novo Nordisk also produces other pharmaceutical products such as growth hormone therapy and treatment for haemophilia, as well as biopharmaceuticals for the treatment of various serious chronic diseases.

Diabetes treatment leader

Novo Nordisk is a leader in the research and development of new diabetes treatments. The company's portfolio includes modern insulins, oral antidiabetic drugs, and devices for insulin delivery. In addition, the company conducts research in several areas related to diabetes, such as obesity and the underlying causes of the disease.

Operations

The company operates in more than 90 countries, and its products are sold in around 180 countries. The majority of Novo Nordisk's sales come from its diabetes care products, but the company also generates significant revenue from its biopharmaceuticals and other pharmaceuticals.

Corporate responsibility

Novo Nordisk is committed to corporate responsibility, as well, it has several ongoing initiatives in areas such as diabetes care, environmental sustainability, and social responsibility. For example, Novo Nordisk has a goal to help improve diabetes care in developing countries through access to education, training, and affordable diabetes care products.

Carbon emissions

In terms of environmental sustainability, the company set a goal to reduce its carbon emissions by 20% by 2020. The company also focuses on water conservation and waste reduction. In addition, Novo Nordisk has a program to support the conservation of biodiversity, which involves protecting the habitats of endangered species and promoting sustainable use of natural resources.

Summary

Novo Nordisk is a leading global pharmaceutical company, with a focus on diabetes care and a commitment to corporate responsibility. Its expertise in research and development, along with its dedication to improving diabetes care in developing countries, and its commitment to environmental sustainability make it a unique and important player in the pharmaceutical industry.

List of products

Nono Nordisk produces a wide range of products, including diabetes medications, haemophilia medications, growth disorder medications, and hormone replacement therapy.

• Its diabetes medications include various types of insulin such as Tresiba, Xultophy, Levemir, Human insulin, Premix insulin and GLP-1 (Rybelsus, Victoza, Ozempic) and Oral antidiabetic agents (NovoNorm), and Obesity medication (Saxenda / Liraglutide 3 mg, Wegovy).
• Haemophilia Medications include NovoSeven, NovoEight, NovoThirteen and Refixia and Esperoct.
• Growth disorder medications include Norditropin, Macrilen and Sogroya are some of the product offered by the company.
• Hormone replacement therapy products include Vagifem, Activelle, Kliogest, Novofem, Trisequens and Estrofem.

External links

• website

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.